

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Formerly known as 培力控股有限公司 in Chinese)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

**LAPSE OF CONNECTED TRANSACTION
IN RELATION TO
DISPOSAL OF ASSETS**

Reference is made to the announcements (the “**Announcements**”) of PuraPharm Corporation Limited (the “**Company**”) dated 8 October 2020 and 25 March 2021 in relation to the connected transaction on a proposed sale of assets. Definitions and terms used in this announcement shall bear the same meanings as defined in the Announcements unless the context otherwise requires.

Pursuant to the Asset Sale Agreement (as supplemented by the supplemental agreement dated 25 March 2021), the completion of the transaction contemplated under the Asset Sale Agreement is conditional upon the satisfaction of the Conditions. If the Conditions have not been satisfied on or before 30 September 2021, the Asset Sale Agreement shall terminate immediately whereupon no parties shall have any rights or claims against any other party without prejudice to any accrued rights or liabilities of any party to the other party in respect of the terms of the Asset Sale Agreement at or before the termination.

As the Conditions have not been fulfilled and the parties to the Asset Sale Agreement have not agreed on any further extension of the Long Stop Date, the Asset Sale Agreement has lapsed on 30 September 2021 and the parties to the Asset Sale Agreement will not enter into the Framework Agreement.

The Directors believe that the lapse of the Asset Sale Agreement and the absence of the Framework Agreement have no material adverse impact on the existing business operations and financial position of the Group.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 5 October 2021

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Directors are Mr. Chow, Stanley and Mr. Cheong Shin Keong; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.